Originalarbeiten

2018

Ramharter M, Schwab M, Mombo-Ngoma G, Zoleko Manego R, Akerey-Diop D, Basra A,  Mackanga J.R,  Würbel H, Wojtyniak JG, Gonzalez R, Hofmann U, Geditz M, Matsiegui P.B, Kremsner P.G, Menendez CKerb R, Lehr T. Population pharmacokinetics of mefloquine intermittent preventive treatment for malaria in pregnancy in Gabon. Antimicrobl Agents and Chemother 2018; Epub: 10.1128/AAC.01113-18 

Balazki P, Schaller S, Eissing T, Lehr T. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of the SGLT inhibitors. CPT Pharmacometrics Syst Pharmacol 2018; Epub: 10.1002/psp4.12359

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network for rifampicin, itraconazole, clarithromycin, midazolam, alfenatil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018; Epub: 10.1002/psp4.12343

Mulyukov Z, Weber S, Pigeolet E, Clemens A, Lehr T, Racine A. Neovascular age-related macular degeneration - a visual acuity model of natural disease progression and ranibizumab treatment effect. CPT Pharmacometrics Syst Pharmacol 2018; Epub: 10.1002/psp4.12322

Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J. Inhibition of Cyclin-dependent kinase 5 - a novel strategy to improve sorafenib responce in HCC therapy. Hepatology 2018; Epub: 10.1002/hep.30190

Schaefer N, Wojtyniak JG, Kroell AK, Koerbel C, Laschke MW, Lehr T, Menger MD, Maurer HH, Meyer MR, Schmidt PH. Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques? Biochem Pharmacol 2018;155:403-418

Lott D, Lehr T, Dingemanse J, Krause A. Modeling tolerance development for the effect on heart rate of the selective S1P1 receptor modulator ponesimod. Clin Pharmacol Ther 2018;103(6):1083-92.

Miller R, Wojtyniak JG, Weckesser LJ, Alexander NC, Engert V, Lehr T. How to disentangle psychobiological stress reactivity and recovery: a comparison of model-based and non-compartmental analyses of cortisol concentrations. Psychoneuroendocrinology 2018;90:194-210.

Schaefer N, Moj D, Lehr T, Schmidt PH, Ramsthaler F. The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine. Int J Legal Med 2018;132(2):415-24.

Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Ammer N, Lehr T. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis. Cancer Chemother Pharmacol 2018;81(2):291-304.

Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC. Population Nutrikinetics of green tea extract. PLoS One 2018, 13(2);e0193074.

2017

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol 2017;80(5):1013-26.

Volz AK, Krause A, Haefeli WE, Dingemanse J, Lehr T. Target-mediated drug disposition pharmacokinetic-pharmacodynamic model of bosentan and Endothelin-1. Clin Pharmacokinet 2017;56(12):1499-511.

Scherer N, Dings C, Böhm M, Laufs U, Lehr T. Alternative treatment regimens with the PCSK9 inhibitors Alirocumab and Evolocumab: a pharmacokinetic and pharmacodynamic modeling approach. J Clin Pharmacol 2017;57(7):846-54.

Lott D, Lehr T, Dingemanse J, Krause A. Impact of demographics, organ impairment, disease, formulation, and food on the pharmacokinetics of the selective S1P1 receptor modulator ponesimod based on 13 clinical studies. Clin Pharmacokinetics 2017;56(4):395-408.

Titze MI, Schaaf O, Hofmann MH, Sanderson MP, Zahn SK, Quant J, Lehr T. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor. Cancer Chemother Pharmacol 2017;79(3):545-58.

Titze MI, Frank J, Ehrhardt M, Smola S, Graf N, Lehr T. A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth. Eur J Pharm Sci 2017;97:38-46.

2016

Lott D, Krause A, Seemayer CA, Strasser DS, Dingemanse J, Lehr T. Modeling the effect of the selective S1P1 receptor modulator ponesimod on subsets of blood lymphocytes. Pharm Res 2017;34(3):599-609.

Titze MI, Schaaf O, Hofmann MH, Sanderson MP, Zahn SK, Quant J, Lehr T. A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques. Cancer Chemother Pharmacol 2016;77(6):1303-1314.

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 2016;65(3):483-9.

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a Phase Ib/IIa study. J Hepatol 2016;65(3):490-8.

Halton JML, Lehr T, Cronin L, Lobmeyer MT, Haertter S, Belletrutti M, Mitchell LG & others. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thromb Haemost 2016;116(3):461-471.

Lott D, Krause A, Dingemanse J, Lehr T. Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects. Eur J Pharm Sci 2016;89:83-93.

Merk H, Zhang S, Lehr T, Müller C, Ulrich M, Bibb JA, Adams RH, Bracher F, Zahler S, Vollmar AM, Liebl J. Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis. Oncotarget 2016;7(5):6088-104.

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J 2017;19(1):298-312.

Schaefer N, Wojtyniak JG, Kettner M, Schlote J, Laschke MW, Ewald AH, Lehr T, Menger MD, Maurer HH, Schmidt PH. Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. Toxicol Lett 2016;253:7-16.

Schneider LS, Ulrich M, Lehr T, Menche D, Müller R, von Schwarzenberg K. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition. Mol Oncol 2016;10(7):1054-1062.

2015

Schneider LS, von Schwarzenberg K, Lehr T, Ulrich M, Kubisch-Dohmen R, Liebl J, Trauner D, Menche D, Vollmar AM. Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer. Cancer Res 2015;75(14):2863-74.

Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - a novel therapeutic approach. J Hepatol 2015;63(1):102-13.

Bortolussi L, Krueger T, Lehr T, Wolf V. Rule-based modelling and simulation of drug-administration policies. Conference Proceedings 2015 Spring Simulation Multi-Conference (SpringSim'15).

2014

Gomez-Mantilla JD, Schaefer UF, Casabo VG, Lehr T, Lehr CM. Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations. AAPS J 2014;16(4):791-801.

Reilly PA*, Lehr T*, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmitz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patients characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY Trial. J Am Coll Cardiol 2014;63(4):321-328; *co-first authors.

2013

Haug KG, Staab A, Dansirikul C, Lehr T. A semi-physiological model of Amyloid-β biosynthesis and clearance in human cerebrospinal fluid: a tool for Alzheimer's disease research and drug development. J Clin Pharmacol 2013;53(7):691-698. 

Liesenfeld KH, Staab A, Härtter S, Formella S, Clemens A, Lehr T. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet 2013;52:453-462.

Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127(13):1404-12.

Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Härtter S, Friedman J, Peters H, Clemens A. Effective elimination of dabigatran by haemodialysis: a phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013;109(4):596-605. 

2012

Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, Friedman J. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012;52(9):1373-8.  

Van De Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, Harper R, Kappetein AP, Lehr T, Mack MJ, Noack H, Eikelboom JW. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012;163(6):931-937.  

Dansirikul C, Lehr T, Liesenfeld KH, Haertter S, Staab A. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost 2012;107(4):775-85.  

Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: Reply to a rebuttal. J Thromb Haemost 2012;10(3):502-4.  

Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, Van Ryn J, Lehr T. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: A pharmacokinetic justification. Curr Med Res Opin 2012;28(2):195-201.  

2011

Lehr T, Yuan J, Hall D, Zimdahl-Gelling H, Schaefer HG, Staab A, MacGregor TR, Jayadev S. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet Genomics 2011;21(11):721-30.  

Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9(11):2168-75.

Lehr T, Yuan J, Zeumer D, Jayadev S, Ritchie MD. Rule based classifier for the analysis of gene-gene and gene-environment interactions in genetic association studies. BioData Mining 2011;4(1).  

2010

Lehr T, Schaefer HG, Staab A. Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling. Pharmacogenet Genomics 2010;20(7):442-50.  

Lehr T, Narbe R, Jöns O, Kloft C, Staab A. Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. J Vet Pharmacol Ther 2010;33(3):277-86.  

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine. AAPS Journal 2010;12(2):117-29.  

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet 2010;49(1):53-66.  

2007-2009

Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin Pharmacokinet 2009;48(8):529-42.  

Lehr T, Staab A, Tillmann C, Nielsen EØ, Trommeshauser D, Schaefer HG, Kloft C. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: A pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 2008;153(1):164-74.  

Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol 2007;64(1):36-48.